Krystal Biotech, Inc. (KRYS) — Fundamental Analysis

Snapshot & Big Picture

Krystal Biotech is a commercial-stage gene therapy company focused on rare skin diseases, best known for VYJUVEK (beremagene geperpavec), its topically administered HSV-1-based gene therapy approved by the FDA in May 2023 for dystrophic epidermolysis bullosa (DEB). The company's story over the past five years is one of dramatic transformation: from a pre-revenue, cash-burning clinical-stage biotech in 2021–2022, to a company generating nearly $390 million in annual revenue by fiscal year 2025 — with genuine operating profitability now firmly established. Krystal carries no meaningful long-term debt, maintains a fortress balance sheet, and is reinvesting selectively in its pipeline while VYJUVEK scales commercially.

Latest Quarter Snapshot (Q1 2026 — Most Current Data)

The most recent data available comes from Krystal's 10-Q filed May 4, 2026, covering the quarter ended March 31, 2026. This is more current than the annual figures and reflects the business's latest trajectory.

At an annualized revenue run-rate of roughly $465 million based on Q1 2026 alone, the company appears to be sustaining strong commercial momentum. Operating and net margins above 46% and 48%, respectively, point to a highly profitable and increasingly scalable business model.

Profitability — Multi-Year Trend

Krystal's profitability evolution is striking. As recently as 2022, the company had zero revenue and was burning through cash, with EBITDA losses exceeding $141 million. The 2023 commercial launch of VYJUVEK began to change the picture rapidly.

*2023 net margin was positive despite an operating loss, likely due to non-operating income (e.g., interest/investment income) on the company's substantial cash holdings.

The trajectory here is exceptional. From deeply negative operating margins in 2023 to over 41% by 2025, Krystal has demonstrated strong operating leverage as VYJUVEK revenues have scaled well ahead of cost growth. EBITDA swung from a -$141 million loss in 2022 to +$167 million in 2025 — a remarkable turnaround in a short timeframe. The Q1 2026 data suggests this improvement is continuing, with operating margins pushing even higher toward 46%.

Financial Health

Krystal's balance sheet is a core strength. The company carries virtually no debt — the debt-to-equity ratio was not reported in annual filings (implying an absence of meaningful long-term debt) and clocked in at just 0.003x in the most recent quarterly filing, effectively zero. Current ratios have remained robust throughout, ranging from roughly 7x to 18x across periods, meaning the company has many multiples of short-term liabilities covered by liquid assets. This financial fortress was built during the pre-revenue years through equity raises and has been reinforced by increasingly strong operating cash flows since commercialization.

Capital Expenditures

CapEx trends tell an interesting story about where Krystal is in its investment cycle:

The CapEx pattern reflects a company that front-loaded its manufacturing and facility investments in 2021–2022 before VYJUVEK was even approved. Once commercialization began, CapEx dropped sharply relative to revenue — falling to just 1.5% of revenue in 2024 — suggesting that the core infrastructure needed to support VYJUVEK's launch was already in place. The modest uptick in 2025 and Q1 2026 is worth watching: it may reflect early-stage investment in manufacturing capacity for pipeline candidates or expansion of existing facilities, but it remains well within a manageable and low-intensity range. Overall, Krystal does not appear to be a capital-intensive business in its current commercial phase, which is a meaningful positive for free cash flow generation.

Growth

Because Krystal had zero revenue in its early years (2021 and 2022), standard multi-year revenue CAGR calculations cannot be meaningfully computed for the standard 3-, 5-, and 10-year windows from the available annual data.

While formal CAGR figures cannot be presented for these windows, the raw revenue trajectory speaks for itself: from $0 in 2022 to $50.7 million in the partial launch year of 2023, then to $290.5 million in 2024 and $389.1 million in 2025. That represents more than a 5x increase in revenue in just two full years of commercial operation, with Q1 2026 suggesting the pace of growth remains strong. This is the kind of rapid commercial scaling rarely seen even in the biotech sector.

Plain English Summary

Krystal Biotech has completed one of the faster and more compelling transformations in recent biotech history — from a money-losing pre-revenue company to a profitable, cash-generating commercial enterprise in just a couple of years, all on the back of a single approved product. VYJUVEK's launch has been a commercial success by virtually every financial measure: revenue is scaling rapidly, margins are expanding sharply, and the business requires relatively modest ongoing capital investment to sustain operations. The balance sheet is clean with essentially no debt and liquidity many times over its short-term obligations. The main risks, as with any single-product biotech, center on commercial concentration — what happens if VYJUVEK faces competitive, reimbursement, or safety headwinds — as well as the challenge of sustaining growth as the addressable DEB patient population becomes more fully penetrated. Pipeline execution will be critical to the company's longer-term growth story. But for now, the financials present a picture of a well-managed, rapidly maturing specialty biotech firing on most cylinders.

Source Filings

• 10-Q filed May 4, 2026 — Quarter ended March 31, 2026
• 10-K filed February 17, 2026 — Fiscal Year ended December 31, 2025